Quote:
Originally Posted by bessiedog
YeAaaa... imma thinkin you have.
Sundance got lil reading fer ya... didja check it out?
Would it be logical for me to automatically discount your other posted research because you posted one that was faulty and thus you have poor research scrutinization skills?
Or would I be doing you a disservice...?
|
https://www.ncbi.nlm.nih.gov/pubmed/30139653
2018 Sep 18;36(39):5825-5831. doi: 10.1016/j.vaccine.2018.08.036. Epub 2018 Aug 20.
Aluminum in vaccines: Does it create a safety problem?
Principi N1, Esposito S2.
Author information
1
Emeritus of Pediatrics, Universitą degli Studi di Milano, Milan, Italy.
2
Pediatric Clinic, Department of Surgical and Biomedical Sciences, Universitą degli Studi di Perugia, Perugia, Italy. Electronic address:
susanna.esposito@unimi.it.
Abstract
For almost a century, aluminum (Al) in the form of Al oxyhydroxide (a crystalline compound), Al hydroxyphosphate (an amorphous Al phosphate hydroxide), Al phosphate, and Al potassium sulfate has been used to improve the immunogenicity of vaccines. Al is currently included in vaccines against tetanus, hepatitis A, hepatitis B, human papillomavirus, Haemophilus influenzae type b, and infections due to Streptococcus pneumoniae and Neisseria meningitidis. Official health authorities consider the inclusion of Al in most of the presently recommended vaccines to be extremely effective and sufficiently safe. However, the inclusion of Al salts in vaccines has been debated for several years because of studies that seem to indicate that chronic Al exposure through vaccine administration can interfere with cellular and metabolic processes leading to severe neurologic diseases. Children, who in their first years of life receive several vaccine doses over a reduced period of time, would be most susceptible to any risk that might be associated with vaccines or vaccine components. The main aim of this paper was to discuss the data presently available regarding Al neurotoxicity and the risk for children receiving vaccines or other pharmaceutical preparations containing Al. Analysis of the literature showed that no apparent reason exists to support the elimination of Al from vaccines for fear of neurotoxicity. The only problem that deserves attention is the suggested relationship between Al oxyhydroxide-containing vaccines and macrophagic myofaciitis or myalgic encephalomyelitis/chronic fatigue syndrome. Currently, definitive conclusions cannot be drawn on these risks and further studies must be conducted. Until then, Al remains the best solution to improve vaccine efficacy.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Bossman
Before you jump on their other point. Remember 1 in 500 risk of your kid dying from measles. 1 in 1,000,000 having a serious complication from the vaccination. You seem like an odd s guy.